Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated

Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated - Effect of Feru-guard

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024063

Enrollment

140

Registered

2016-09-15

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

Test food:capsule(ferulic acid, garden angelica) Administration period:48weeks Test food:capsule(not contained ferulic acid, garden angelica) Administration period:48weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. stuff forget there is complained of, that is supported by family and friends if possible 2. The general cognitive function is normal 3. housework and ADL, including the work it is generally normal 4. it is not a dementia 5.MMSE-J score more than 24 points 6.GDS-S-J is less than or equal to 5 points 7.ADAS-Jcog. Is less than or equal to 10 points or more three-point 8. MCIS score until the zero point below 49.8 points 9. Age is less than 85 years of age or 65 years of age

Exclusion criteria

Exclusion criteria: 1. Patients who have merged the neurodegenerative disease which presents a dementia-like symptoms, or there is a suspicion Parkinson's disease, Huntington's disease, Down's syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, cortical basal degeneration, etc. 2. patient suspected failure in cognitive function due to causes of the following Vascular dementia, metabolic diseases (hypothyroidism, vitamin B12 hypothyroidism, folic acid deficiency, etc.), head trauma, normal pressure hydrocephalus 3. Patients with delirium due to drug addiction Patients 4. there is a history of the following disease onset before Alcoholism, stroke, depression, manic state, schizophrenia 5. malignant neoplasm, patients with acute inflammatory disease 6. Patients have experience taking Feru-guard in the past 7. Patients have medication anti-dementia drugs 8. CDR-J 1 or more 9. HbA1c 8.0 or higher 10. If clear metabolic syndrome 11. Other 12. If the principal investigator or researcher has determined that improper participation in the present study

Design outcomes

Primary

Measure	Time frame
Clinical Gloval Impression Criteria: Changes of cognitive impairment in comparison with before intervention. 1. Remarkable improvement of MCI 2. Improvement of MCI 3. No change 4. Hypofunction of cognitive Term: 24weeks, 48weeks	—

Secondary

Measure	Time frame
ADAS-jcog MMSE RBMT	—

Countries

Japan

Contacts

Public ContactShinya Yamamoto

Glovia Co., Ltd. Department of clinical research

yamamoto@glovia.co.jp03-6228-3376

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026